Page contentsPage contents Revision 1 Current effective version Document history Related content Topics This document provides product-specific guidance on the demonstration of the dronedarone. Keywords:Â Bioequivalence, generics, dronedarone Abbreviations: BCS Classification: Biopharmaceutics Classification System AUC0-t: area under the plasma concentration curve from administration to last observed concentration at time t AUC0-72: area under the plasma concentration curve from administration to last observed concentration at 72 hours Cmax: maximum plasma concentration Revision 1 Dronedarone film-coated tablets 400 mg product-specific bioequivalence guidance - Revision 1Draft: consultation closed Consultation dates: 10/07/2025 to 31/10/2025 Reference Number: EMA/151695/2025 Rev. 1 English (EN) (158.79 KB - PDF)First published: 10/07/2025 View Current effective version Dronedarone film-coated tablets 400 mg product-specific bioequivalence guidance - First versionAdopted Reference Number: EMA/CHMP/356875/2017 Legal effective date: 01/08/2018 Summary: This guidance provides product-specific guidance on the demonstration of the dronedarone. English (EN) (76.18 KB - PDF)First published: 01/02/2018 Last updated: 01/02/2018 View Document history Draft dronedarone film-coated tablets 400 mg product-specific bioequivalence guidance - First versionDraft: consultation closed Consultation dates: 28/07/2017 to 31/10/2017 Reference Number: EMA/CHMP/356875/2017 Summary: This document provides product-specific guidance on the demonstration of the bioequivalence of dronedarone film-coated tablets English (EN) (76.44 KB - PDF)First published: 28/07/2017 Last updated: 28/07/2017 View Related content Investigation of bioequivalence Concept paper on the development of product-specific guidance on demonstration of bioequivalence Topics Scientific guidelines Share this page